Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

SML2569

Sigma-Aldrich

JH-II-127

≥98% (HPLC)

Synonym(s):

[4-[[5-Chloro-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-3-methoxyphenyl]-4-morpholinylmethanone

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
¥13,600
25 MG
¥54,830

¥13,600

Check Cart for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
¥13,600
25 MG
¥54,830

About This Item

Empirical Formula (Hill Notation):
C19H21ClN6O3
CAS Number:
1700693-08-8
Molecular Weight:
416.86
MDL number:
MFCD29472241
UNSPSC Code:
12352200
NACRES:
NA.77

¥13,600

Check Cart for Availability
Request a Bulk Order

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

Clc1c2c(nc([nH]c2NC)Nc3c(cc(cc3)C(=O)N4CCOCC4)OC)nc1

InChI

1S/C19H21ClN6O3/c1-21-16-15-12(20)10-22-17(15)25-19(24-16)23-13-4-3-11(9-14(13)28-2)18(27)26-5-7-29-8-6-26/h3-4,9-10H,5-8H2,1-2H3,(H3,21,22,23,24,25)

InChI key

HUEKBQXFNHWTQQ-UHFFFAOYSA-N

Biochem/physiol Actions

JH-II-127 is an orally available, brain penetrant, potent and selective inhibitor of both wild-type and G2019S mutant Leucine-rich repeat kinase 2 (LRRK2). JH-II-127 inhibits phosphorylation of the Ser910 and Ser935 of both wild-type and G2019S mutant LRRK2. It causes complete inhibition of LRRK2 in mouse brain at 100 mg/kg.
orally available, brain penetrant, potent and selective inhibitor of both wild-type and G2019S mutant Leucine-rich repeat kinase 2 (LRRK2)

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SML2569-VAR:
SML2569-5MG:
SML2569-BULK:
SML2569-25MG:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

John M Hatcher et al.
ACS medicinal chemistry letters, 6(5), 584-589 (2015-05-26)
Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target. Here we report a 2-anilino-4-methylamino-5-chloropyrrolopyrimidine, JH-II-127 (18), as a potent and selective inhibitor of both
Farzaneh Atashrazm et al.
Clinical pharmacology : advances and applications, 8, 177-189 (2016-11-02)
Major advances in understanding how genetics underlies Parkinson's disease (PD) have provided new opportunities for understanding disease pathogenesis and potential new targets for therapeutic intervention. One such target is leucine-rich repeat kinase 2 (LRRK2), an enigmatic enzyme implicated in both

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service